HHS ruling on Plan B introduces new risk for drugmakers.
Cassandra
C
Willyard
D000293:Adolescent; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015195:Drug Design; D004345:Drug Industry / Q000331:legislation & jurisprudence; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage*; D011247:Pregnancy; D011640:Public Policy / Q000331:legislation & jurisprudence*; D012586:Science; D014481:United States; D014483:United States Dept. of Health and Human Services / Q000331:legislation & jurisprudence*; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence
D003271:Contraceptive Agents, Female; D016912:Levonorgestrel